group, you will not benefit from the vaccine. You will be screened for syphilis and HIV infection and some of your blood tests will show if you have other conditions such as severe anaemia which you may not have been aware of. Your participation in this study is important to learn how people respond to these vaccines. It will help in the development of vaccines to prevent Ebola and may in the future help people all over the world. WHO WILL BE ABLE TO SEE MY INFORMATION? We will keep your study information private. All files with information that could identify you will be kept in locked cabinets. Samples of blood that are collected from you will be marked with a number that tells the study team that it is your blood. These samples will not be marked with your name. We may take your fingerprint or a picture of your eyes to help us identify you during the study. We will keep a copy of your fingerprint or eye picture in a secure computer file. The monitor(s), the auditor(s) of the sponsors and collaborators, the IRB/IEC, and the regulatory authority(ies) will be granted direct access to your original medical records for verification of clinical trial procedures and/or data, without violating your confidentiality, to the extent permitted by the applicable laws and regulations and that, by signing a written informed consent form, you or your legally acceptable representative is authorizing such access. WHO IS WATCHING OVER THIS STUDY? A Data and Safety Monitoring Board (DSMB) will be looking at the study information very often. The DSMB is made up of doctors and other people who are not directly involved in the study and who have a good understanding of Ebola and vaccine studies. The DSMB may decide to stop the study earlier than planned if they think it is not safe anymore or will not be able to find out if these vaccines work. WHAT ELSE SHOULD I KNOW ABOUT THIS STUDY? A description of this study will be on the internet at http://www.ClinicalTrials.gov. This website will not include information about you. At most, the website will include a summary of the results. You can search this website at any time. The United States National Institutes of Health (NIH) researchers must tell the NIH at least yearly about any stock they own in the companies that make the study vaccines. All study investigators are also asked to do this. If you would like to get more information, you may ask your study team. WHO CAN I TALK TO ABOUT THIS STUDY? If you want to talk to anyone about this research study because you think you have been hurt by being part of the study, or if you have any questions about the study, 1. Introduction a. Background to the 2013-15 outbreak: On December 6, 2013, Emile Ouamouno, a 2-year-old from Meliandou, a small village in the Guinea forestière, died after four days of suffering from vomiting, fever, and black stool. 1 The cause of his infection is unknown, although he is now widely considered to be the index case for the outbreak of Ebola hemorrhagic fever now Ebola Virus Disease (EVD). Within a month, the child’s sister, mother, and grandmother died after experiencing similar symptoms.3 The funeral for the latter was attended by a midwife who passed the disease to relatives in another village, and to a health care worker treating her.4 That health care worker was treated at a hospital in Macenta, about 80 kilometers (50 miles) east. A doctor who treated her contracted Ebola. The doctor then passed it to his brothers in Kissidougou, 133 kilometers (83 miles) away. 4 Although the outbreak of EVD originated in Guinea, between December 2013 and March 2014, it spread more rapidly in the eastern regions of Sierra Leone and then in North Central Liberia, followed by Nzérékoré in Guinea. 5 Between December 2013 and April 10, 2016, a total of 28,616 suspected, probable, and confirmed cases of Ebola virus disease (EVD) were reported. 5 A total of 11,310 deaths were attributed to the outbreak. 5 The largest numbers of cases and deaths occurred in Guinea, Liberia, and Sierra Leone, but 36 cases were reported from Italy, Mali, Nigeria, Senegal, Spain, the United Kingdom, and the United States.6 After reaching a peak of 950 confirmed cases per week in September 2014, the incidence dropped precipitously toward the end of that year. 5 Epidemiological investigations have revealed that primary human infections with the Ebola virus are associated with the handling of infected chimpanzees, gorillas, fruit bats, monkeys, forest antelope and porcupines. 2 Human-to-human transmission of Ebola occurs through close and direct physical contact with infected bodily fluids, the most infectious being blood, feces and vomit. 7 Funeral practices in the region that involved touching and washing dead bodies as well as the unsanitary conditions in many healthcare facilities magnified the risks of human-to-human transmission in the infection, treatment, and death cycles. 7 The 2013-15 outbreak was the 24th known outbreak of Ebola and by far the most severe. 8 A new outbreak occurred in the Democratic Republic of Congo in May, 2017 and then the following year on April 4, 2018.9 For the latter outbreak, a total of 38 laboratory confirmed and 15 probable cases (deaths for which it was not possible to collect laboratory specimens for testing) have been reported. Of these 53 cases, 29 died, giving a case fatality ratio of 54.7%. On August 1,